Table 2.
Response Assessment to Bevacizumab-Based Treatment
| Entire Cohort, n = 22 | |
|---|---|
| n (%) | |
| Best clinical response to bevacizumab-based treatment | |
| Stable disease | 6 (27.3) |
| Improvement | 14 (63.6) |
| Progressive disease | 2 (9.1) |
| Best radiological intracranial response to bevacizumab-based treatment (T2/FLAIR); n = 20 | |
| Stable T2/FLAIR | 8 (40.0) |
| Improvement of T2/FLAIR (>25%) | 6 (30.0) |
| “Significant” decrease of T2/FLAIR (>50%) | 6 (30.0) |
| “Significant increase” of T2/FLAIR (>25%) | 0 (0.0) |
| Best radiological intracranial response to bevacizumab-based treatment based on RANO-BM (T1 GBCA [Gd-based contrast agent]); n = 19 | |
| Stable disease | 9 (47.3) |
| Partial response | 7 (36.8) |
| Progressive disease | 3 (15.7) |
| Reduction of steroid treatment | |
| Yes | 15 (68.2) |
| No | 7 (31.8) |
| Reason for determination of bevacizumab-based treatment | |
| Progression | 9 (40.9) |
| Toxicity | 5 (22.7) |
| Other/Unclear | 7 (31.8) |
| On-going | 1 (4.5) |
| Extracranial progression after bevacizumab-based treatment | |
| Yes | 11 (50.0) |
| No | 11 (50.0) |
| Intracranial progression after bevacizumab-based treatment | |
| Yes | 15 (68.2) |
| No | 7 (31.8) |
| Alive at last follow-up | |
| Yes | 3 (13.6) |
| No | 19 (86.4) |
| Median time to intracranial progression or death, months (range) | 8 (1–24) |
| Median overall survival time from the start of bevacizumab-based treatment, months (range) | 17 (1–43) |